Compare Robinhood Markets, Inc. (HOOD) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Novavax Inc — how do they compare? Robinhood Markets, Inc. trades at $109.02 (market cap $96.21B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Robinhood Markets, Inc. is far larger — about 52.9× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Novavax Inc for 59 Days on average.
| HOOD | NVAX | |
|---|---|---|
Market Cap | $96.21B | $1.82B |
Volume | 22,572,153 | 6,198,505 |
Sector | Financials | Health |
52-Week High | $152.46 | $12.56 |
52-Week Low | $65.16 | $6.22 |
Typical Hold Time | 75 Days | 59 Days |
Enterprise Value | $102.75B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $107.01, down 2.28% today, amid a bullish technical setup with support at $105 and resistance at $109. The company reported strong 2025 results with revenue of $4.47 billion and net income of $1.88 billion, though Q1 2026 earnings missed expectations. Recent news highlights expansion into 24/7 stock trading and new product launches aimed at boosting engagement.
Outlook remains positive with a consensus price target of $137.53, implying 28% upside, supported by 77% analyst buy ratings. Key risks include high valuation multiples (P/E 47.35) and reliance on retail trading growth, while regulatory scrutiny and market volatility pose challenges to sustained momentum.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
